BURLINGTON, Mass., Jan. 31, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2021, the continued uptake of Novartis/Incyte's recently launched JAK-2 inhibitor Jakafi (ruxolitinib) will be the greatest driver of growth in the myelofibrosis therapy market in the United States and Europe. Since only a small percentage of patients are eligible for allogeneic stem-cell transplantation—the lone curative treatment for myelofibrosis—the only care available for most patients is treatment of disease symptoms. According to interviewed experts, the entry of ruxolitinib is a significant advance in myelofibrosis treatment because they believe the drug offers clear improvements in constitutional symptoms and reduces the severe splenomegaly experienced by many patients, resulting in an overall better quality of life.
According to Niche Markets and Rare Diseases: Myelofibrosis, JAK-2 inhibition is the focus of considerable development activity in myelofibrosis and up to five new JAK-2 inhibitors could launch for the disease through 2021. Clinical trial data from long-term evaluation of myelofibrosis patients indicated that ruxolitinib improves overall survival in addition to providing sustained relief of constitutional symptoms—these recent analyses will likely accelerate uptake of ruxolitinib and other JAK-2 inhibitors.
"The most promising emerging JAK-2 inhibitor—YM Biosciences' CYT-387—has attracted interest from physicians because early phase trials have shown an effect on anemia in addition to an effect on constitutional symptoms," said Decision Resources Senior Vice President Cynthia Mundy, Ph.D. "Also, Gilead's recent decision to acquire YM Biosciences to gain access to the drug suggests Gilead expects CYT-387 to emerge as a formidable competitor to ruxolitinib and that this agent could capture substantial market share."
The report also finds that, although interviewed experts are enthusiastic about treatments that offer better management of myelofibrotic symptoms and improvements in quality of life, they indicate they are likely to continue using conventional treatment regimens in many of their patients, particularly those assessed as having lower risk. As a result, although ruxolitinib will experience significant adoption in the myelofibrosis market, hydroxyurea (Bristol-Myers Squibb's Hydrea, generics) will continue to be widely used to treat constitutional symptoms. Similarly, Celgene's emerging immunomodulator pomalidomide will not displace use of the older, related drugs—Celgene's Thalomid and Revlimid (lenolidomide).
Myelofibrosis is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources